Top Clicks This Month

Not Intended for Therapeutic Use. For research use only.

Doxorubicin - CAS 23214-92-8

Quick Inquiry

Name:
* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Category
ADCs
Product Name
Doxorubicin
Catalog Number
23214-92-8
Synonyms
Adriamycin
CAS Number
23214-92-8
Description
Doxorubicin(Adriamycin) is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.
Molecular Weight
543.52
Molecular Formula
C27H29NO11
COA
Inquire
MSDS
Inquire
Targets
Topo II
Structure
CAS 23214-92-8 Doxorubicin
Specification
Purity
>98%
Application
ADCs Cytotoxin
Related Products
Reference Reading
1. Multiwalled carbon nanotube–doxorubicin supramolecular complexes for cancer therapeutics
Hanene Ali-Boucetta, Khuloud T. Al-Jamal, Kostas Kostarelos*. Chem. Commun., 2008, 459–461
In this communication, we describe a previously unreported non-covalent multiwalled nanotube (MWNT)–doxorubicin supra-molecular complex that can be developed for cancer therapy. We have investigated the ability of doxorubicin to interact non-covalently with very thin, pristine MWNT 1 at various mass ratios and evaluated their capability to kill human breast cancer cells. Doxorubicin belongs to a clinically-used family of anthracyclines, therefore constitutes one of the best candidates to test non-covalent complexation with MWNTs. Moreover, doxorubicin 3 is a fluorescent molecule with a chromophore composed of three planar and aromatic hydroxyanthraquinonic rings that are used to monitor its supramolecular interaction with MWNTs. MWNTs were dispersed in water using the tri-block copolymer.
2. Synthesis, in vitro and in vivo anticancer activity of novel 1-(4-imino-1-substituted-1H-pyrazolo[3,4-d] pyrimidin-5(4H)-yl)urea derivatives
Chandra Bhushan Mishra, Raj Kumar Mongre, Shikha Kumari, Dong Kee Jeong* and Manisha Tiwari*. RSC Adv.,2016, 6, 24491–24500
To study apoptosis by flow cytometer, A549 cells were treated with CBS-1 (5 μM and 10 μM) and doxorubicin (10 μM) for 24 h. In result, CBS-1 at 10 μM concentration showed significant (p <0.05) apoptosis against A549 cells and it was found better than doxorubicin (10 μM) as shown in Fig. 6 and Table 3. Result points out that CBS-1 (10 μM) showed 50.98% apoptosis and while doxorubicin (10 mM) displayed 22.74% apoptosis in 24 h. Thus, Hoechst 33342 staining and flow cytometry studies evidently indicate that CBS-1 (10 mM) showed better apoptosis against A549 cells as compared to doxorubicin.
3. Multifunctional ATRP based pH responsive polymeric nanoparticles for improved doxorubicin chemotherapy in breast cancer by proton sponge effect/endo-lysosomal escape
Shantanu V. Lale, Arun Kumar, Farhat Naz, Alok C. Bharti and Veena Koul*. Polym. Chem.,2015, 6,2115–2132
Polymer nanoparticles (NPs) for doxorubicin delivery in breast cancer have been investigated by many researchers to overcome the cardiotoxicity, non-specificity and acquired resistance of cancer cells to current doxorubicin chemotherapy. Polymeric nanoparticles help to improve the bioavailability of doxorubicin by passive targeting of tumors via an enhanced permeation and retention (EPR) effect, by increasing the circulation half-life of doxorubicin and by overcoming acquired cancer cell resistance. These polymeric nanosystems suffer from few drawbacks, which lead to a decreased antitumor efficacy of doxorubicin. Doxorubicin hydrochloride is a water-soluble drug, which makes it difficult to physically load doxorubicin into nanoparticles in sufficient amounts.
2005 - BOC Sciences | All rights reserved
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE